Comparative Pharmacology
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus MONISTAT 1 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus MONISTAT 1 COMBINATION PACK.
BUTENAFINE HYDROCHLORIDE vs MONISTAT 1 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Miconazole inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and leads to fungal cell death. Miconazole also has direct anti-inflammatory and antibacterial properties.
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
Miconazole nitrate 1200 mg vaginal suppository inserted intravaginally once at bedtime; plus external miconazole nitrate 2% cream applied to affected area twice daily for up to 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Terminal elimination half-life: 24-30 hours (range 20-50 hours). Clinical context: Once-daily dosing may be considered for some indications, but prolonged half-life supports weekly or twice-weekly regimens for systemic infections.
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
Fecal: Approximately 90% of absorbed dose; Renal: <2% as unchanged drug; Biliary: Minor, less than 10%.
Category C
Category C
Antifungal
Antifungal